ONC (BeOne Medicines) Short Interest


ONC BeOne Medicines Ltd ONC
81 GF Score
Price $280.00
GF Value $366.06
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ONC vs RVMD, RPRX, BNTX: Short Interest Comparison

For the Biotechnology subindustry, BeOne Medicines's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BeOne Medicines Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Short Interest distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Short Interest falls into.


ONC
81GF Score
BeOne Medicines Ltd ONC
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $280.00 is trading 23.5% below its estimated GF Value™ of $366.06. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Short Interest:
  • GF Value™: $366.06 vs. price of $280.00 (23.5% below fair value)
  • GF Score™: 81/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score

Get the complete analysis for ONC

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$280.00
Price
$366.06
GF Value